ClinicalTrials.gg
TerminatedNCT01163253Updated Jun 26, 2017Results posted

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of CP-690,550 and CP-690,550 in Psoriasis, sponsored by Pfizer. Terminated at 323 sites in 36 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-26.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,867
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.

Enrollment
Largest of 19
2,867 · median 135
Started
2010
with 2 others
Phase 3
9 of 19
1 open now
Registered
3rd of 19
by date
Lead sponsor
14 of 19
Pfizer

Among the 19 studies testing tofacitinib in Psoriasis, this one has the largest enrollment, is one of 3 that started in 2010, is one of 9 in phase 3, and was the 3rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tofacitinib in Psoriasis, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the qualifying studies with CP-690,550 providing entry criteria is met.

Read the detailed description

The study terminated on 08MAR2016 as it met its objectives of characterizing long term safety and tolerability. The study did not terminate due to safety concerns.

03

Conditions studied

  • Psoriasis

Keywords

  • chronic
  • severe
  • treatment
  • safety
  • CP-690,55
  • Plaque Psoriasis
  • Psoriasis Vulgaris
  • Xeljanz
  • Tofacitinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have participated in qualifying study with CP-690,550 and are 18 years or older with diagnosis of plaque-type psoriasis (psoriasis vulgaris).

Exclusion criteria

Exclusion Criteria:

  • Non-plaque or drug induced forms of psoriasis;
  • Cannot discontinue current oral, injectable or topical therapy for psoriasis or cannot discontinue phototherapy (PUVA or UVB).
  • Any uncontrolled significant medical condition.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,867 participants (actual)

Study arms

  • Experimental
    Active Treatment

    The study is anticipated to continue for up to at least 2 years post First Market Approval (FMA) in a global, major market. All subjects will receive 10 mg BID of CP-690,550 for first 3 months of trial. Study has the option for variable dosing with 5 mg or 10 mg BID after first 3-months of treatment based on PI discretion

    Drug: CP-690,550

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 4 weeks after last dose (up to 67 months) that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.

    Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)

  2. Number of Adverse Events (AEs) by Severity

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories: a) mild: AEs did not interfere with participant's usual function; b) moderate: AEs interfered to some extent with participant's usual function; c) severe: AEs interfered significantly with participant's usual function.

    Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)

  3. Number of Participants With Laboratory Abnormalities

    Abnormality criteria: hematology (hemoglobin, hematocrit, red blood cell \<0.8\*lower limit of normal \[LLN\]; reticulocyte\<0.5\*LLN,\>1.5\*ULN; platelets\<0.5\*LLN,\>1.75\* upper limit of normal \[ULN\]; WBC\<0.6\*LLN, \>1.5\*ULN; lymphocytes, neutrophils, basophils, eosinophils, monocytes\<0.8\*LLN; \>1.2\*ULN; coagulation (prothrombin \[PT\], PT ratio\>1.1\*ULN) liver function (bilirubin\>1.5\*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma GT\>0.3\*ULN, protein, albumin\<0.8\*LLN; \>1.2\*ULN, globulin\<0.5\*LLN; \>1.5\*ULN); renal function (blood urea nitrogen, creatinine\>1.3\*ULN); electrolytes(sodium\<0.95\* LLN; \>1.05\* ULN, potassium, chloride, calcium, bicarbonate\<0.9\*LLN; \>1.1\*ULN), chemistry (glucose\<0.6\*LLN; \>1.5\* ULN), urinalysis (pH \<4.5;\>8, glucose, ketones, protein, blood, urobilinogen, nitrite, bilirubin, leukocyte esterase\>=1; RBC, WBC\>=20); lipids (cholesterol \[C\], LDL-C \>1.3\*ULN, HDL-C\<0.8\*LLN, triglycerides\>1.3\* ULN), hormones(T4, T3, T4, TSH\<0.8\* LLN; \>1.2\* ULN).

    Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)

  4. Change From Baseline in Hemoglobin Level at Month 1

    Time frame: Baseline, Month 1

  5. Change From Baseline in Hemoglobin Level at Month 3

    Time frame: Baseline, Month 3

  6. Change From Baseline in Hemoglobin Level at Month 6

    Time frame: Baseline, Month 6

  7. Change From Baseline in Hemoglobin Level at Month 12

    Time frame: Baseline, Month 12

  8. Change From Baseline in Hemoglobin Level at Month 24

    Time frame: Baseline, Month 24

  9. Change From Baseline in Hemoglobin Level at Month 36

    Time frame: Baseline, Month 36

  10. Change From Baseline in Hemoglobin Level at Month 48

    Time frame: Baseline, Month 48

  11. Change From Baseline in Lymphocyte and Neutrophil Count at Month 1

    Time frame: Baseline, Month 1

  12. Change From Baseline in Lymphocyte and Neutrophil Count at Month 3

    Time frame: Baseline, Month 3

  13. Change From Baseline in Lymphocyte and Neutrophil Count at Month 6

    Time frame: Baseline, Month 6

  14. Change From Baseline in Lymphocyte and Neutrophil Count at Month 12

    Time frame: Baseline, Month 12

  15. Change From Baseline in Lymphocyte and Neutrophil Count at Month 24

    Time frame: Baseline, Month 24

  16. Change From Baseline in Lymphocyte and Neutrophil Count at Month 36

    Time frame: Baseline, Month 36

  17. Change From Baseline in Lymphocyte and Neutrophil Count at Month 48

    Time frame: Baseline, Month 48

  18. Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 1

    Time frame: Baseline, Month 1

  19. Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 3

    Time frame: Baseline, Month 3

  20. Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 6

    Time frame: Baseline, Month 6

  21. Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 12

    Time frame: Baseline, Month 12

  22. Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 24

    Time frame: Baseline, Month 24

  23. Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 36

    Time frame: Baseline, Month 36

  24. Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 48

    Time frame: Baseline, Month 48

  25. Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 1

    Time frame: Baseline, Month 1

  26. Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 3

    Time frame: Baseline, Month 3

  27. Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 6

    Time frame: Baseline, Month 6

  28. Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 12

    Time frame: Baseline, Month 12

  29. Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 24

    Time frame: Baseline, Month 24

  30. Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 36

    Time frame: Baseline, Month 36

  31. Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 48

    Time frame: Baseline, Month 48

  32. Number of Participants With Clinically Significant Change From Baseline in Physical Examination

    Physical examinations included: general appearance; skin, head, eyes, ears, nose and throat; heart; lungs; abdomen; lower extremities (for the presence of peripheral edema) and lymph nodes. Clinical significance of change from baseline values in physical examination was based on investigator's discretion.

    Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)

  33. Number of Participants With Vital Sign Abnormalities

    Criteria for abnormalities in vital signs included: Systolic blood pressure (SBP): less than (\<) 90 millimeter of mercury (mmHg) and maximum increase from baseline (IFB) of greater than or equal to (\>=) 30 mmHg; diastolic blood pressure (DBP): \<50 and greater than (\>) 120 mmHg and maximum IFB of \>=20 mmHg; heart rate: \<40 and \>120 beats per minute.

    Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)

  34. Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 1

    Time frame: Baseline, Month 1

  35. Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 3

    Time frame: Baseline, Month 3

  36. Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 6

    Time frame: Baseline, Month 6

  37. Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 12

    Time frame: Baseline, Month 12

  38. Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 24

    Time frame: Baseline, Month 24

  39. Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 36

    Time frame: Baseline, Month 36

  40. Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 48

    Time frame: Baseline, Month 48

  41. Change From Baseline in Heart Rate at Month 1

    Time frame: Baseline, Month 1

  42. Change From Baseline in Heart Rate at Month 3

    Time frame: Baseline, Month 3

  43. Change From Baseline in Heart Rate at Month 6

    Time frame: Baseline, Month 6

  44. Change From Baseline in Heart Rate at Month 12

    Time frame: Baseline, Month 12

  45. Change From Baseline in Heart Rate at Month 24

    Time frame: Baseline, Month 24

  46. Change From Baseline in Heart Rate at Month 36

    Time frame: Baseline, Month 36

  47. Change From Baseline in Heart Rate at Month 48

    Time frame: Baseline, Month 48

  48. Number of Participants With Electrocardiogram (ECG) Abnormalities

    Criteria for ECG abnormality: PR interval \>=300 milliseconds (msec); QT interval \>=500 msec; QTcB (Bazett's Correction) and QTcF (Fridericia's Correction) 450 to \<480 msec, 480 to \<500 msec and \>=500 msec.

    Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)

  49. Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 6

    Time frame: Baseline, Month 6

  50. Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 12

    Time frame: Baseline, Month 12

  51. Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 24

    Time frame: Baseline, Month 24

  52. Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 36

    Time frame: Baseline, Month 36

  53. Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 48

    Time frame: Baseline, Month 48

  54. Number of Participants With Adjudicated Cardiovascular Events

    Adjudicated cardiovascular events were assessed by adjudication committee as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; as applicable.

    Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)

  55. Number of Participants With Malignancy Events

    Malignancy events included lymphoma, and demyelinating neurologic events. Biopsies collected for malignancy events were submitted to the central laboratory for pathologist over-read.

    Time frame: Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)

Secondary outcomes

  1. Percentage of Participants Achieving Physician Global Assessment (PGA) Response of 'Clear' or 'Almost Clear'

    The PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema (E), induration (I), and scaling (S) across all psoriatic lesions in participants. The severity rating scores (Erythema: 0= no evidence of erythema to 4= dark, deep red; Induration: 0= no evidence of plaque elevation to 4= marked plaque elevation, hard/sharp borders; Scaling: 0= no evidence of scaling to 4= thick, coarse scale predominates) were summed (E + I + S = total) and the average (total/3) was taken. The total average was rounded to the nearest whole number score to determine the PGA. The 5-point scale for PGA was: 0= clear; 1= almost clear; 2= mild; 3= moderate; 4= severe, where higher score indicated more severity of psoriasis. Percentage of participants with response of 'clear' (score of '0') and 'almost clear' (score of '1') were reported.

    Time frame: Month 1, 3, 6, 12, 24, 36, 48

  2. Percentage of Participants Achieving Greater Than or Equal to (>=) 75 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores

    PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=75 percent (%) reduction from baseline in PASI scores were reported.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  3. Psoriasis Area and Severity Index (PASI) Scores

    PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  4. Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores at Month 1, 3, 6, 12, 24, 36 and 48

    PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  5. Psoriasis Area and Severity Index (PASI) Component Scores: Erythema

    PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Erythema was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  6. Psoriasis Area and Severity Index (PASI) Component Scores: Induration

    PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Induration was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  7. Psoriasis Area and Severity Index (PASI) Component Scores: Scaling

    PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Scaling was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  8. Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Erythema at Month 1, 3, 6, 12, 24, 36 and 48

    PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Erythema was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  9. Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Induration at Month 1, 3, 6, 12, 24, 36 and 48

    PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Induration was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  10. Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Scaling at Month 1, 3, 6, 12, 24, 36 and 48

    PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Scaling was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  11. Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores

    PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=50% reduction from baseline in PASI scores were reported.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  12. Percentage of Participants Achieving Greater Than or Equal to (>=) 90 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores

    PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=90% reduction from baseline in PASI scores were reported.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  13. Percentage of Participants Achieving Greater Than or Equal to (>=) 125 Percent Increase From Baseline in Psoriasis Area and Severity Index (PASI) Scores

    PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=125% increase from baseline in PASI scores were reported.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  14. Itch Severity Item (ISI) Scores

    ISI assessed severity of itching due to psoriasis. ISI was a single item, horizontal numeric rating scale. Participants were asked to rate their 'severity of itching' due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms '0=no itching' and '10=worst possible itching' at the ends. Higher scores indicated greater severity of itching.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  15. Change From Baseline in Itch Severity Item (ISI) Scores at Month 1, 3, 6, 12, 24, 36 and 48

    ISI assessed severity of itching due to psoriasis. ISI was a single item, horizontal numeric rating scale. Participants were asked to rate their 'severity of itching' due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms '0=no itching' and '10=worst possible itching' at the ends. Higher scores indicated greater severity of itching.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  16. Dermatology Life Quality Index (DLQI) Scores

    The DLQI was a validated, self-administered, 10-item quality-of-life questionnaire that consisted of 10 items that assessed the impact of skin disease on quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Each question was scored on a scale of 0=not at all/not relevant to 3=very much. Response from all of the 10 questions were added to derive the DLQI total scores. Total DLQI scores ranges from 0=not at all to 30=very much, with higher scores indicating greater impairment in quality of life.

    Time frame: Baseline, Month 1, 6, 12, 24, 36, 48

  17. Change From Baseline in Dermatology Life Quality Index (DLQI) Scores at Month 1, 6, 12, 24, 36 and 48

    The DLQI was a validated, self-administered, 10-item quality-of-life questionnaire that consisted of 10 items that assessed the impact of skin disease on quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Each question was scored on a scale of 0=not at all/not relevant to 3=very much. Response from all of the 10 questions were added to derive the DLQI total scores. Total DLQI scores ranges from 0=not at all to 30=very much, with higher scores indicating greater impairment in quality of life.

    Time frame: Baseline, Month 1, 6, 12, 24, 36, 48

  18. 36-Item Short-Form (SF-36) Health Survey Version 2, Acute: Physical Component Summary Scores

    The SF-36 questionnaire, version 2, acute was a 36-item generic health status measure. SF-36 evaluated 8 health-related aspects of an individual: physical functioning, role-physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition. Two summary scale scores were computed from the 8 health aspect scores: physical component summary score and mental component summary score. Score range for both summary scales ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition.

    Time frame: Baseline, Month 6, 12, 24, 36, 48

  19. 36-Item Short-Form (SF-36) Health Survey Version 2, Acute: Mental Component Summary Scores

    The SF-36 questionnaire, version 2 was a 36-item generic health status measure. SF-36 evaluated 8 health-related aspects of an individual: physical functioning, role-physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition. Two summary scale scores were computed from the 8 health aspect scores: the Physical Component Summary and the Mental Component Summary. Score range for both summary scale ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition.

    Time frame: Baseline, Month 6, 12, 24, 36, 48

  20. Number of Participants With Patient Global Assessment (PtGA) Response of "Clear" or "Almost Clear"

    The PtGA evaluated the overall skin disease of participants at that point in time on a single-item. Participants provided their response on a 5-point scale ranges from: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe. Higher score indicated greater severity of disease. Participants who provided their response as "clear (score of 0)" or "almost clear (score of 1)" in PtGA at each specified visit were reported in this outcome measure.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

  21. Euro Quality of Life- 5-Dimensions (EQ-5D)-Utility Scores

    EQ-5D: participant rated 5-dimension (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression) questionnaire to assess health-related quality of life in terms of a single utility score. Each dimension was assessed on a 3-point scale (1=no problems, 2=some problems, 3=extreme problems, where higher scores=worse health condition). The responses from the 5 dimensions were used to calculate a single utility index value. Scoring formula developed by EuroQol Group assigned a utility value for each dimension in the profile. Score was transformed and results in a total score range -0.594 to 1.000; higher score indicated a better health state.

    Time frame: Baseline, Month 6, 12, 24, 36, 48

  22. Euro Quality of Life-5-Dimensions (EQ-5D)-Visual Analogue Scale Scores (VAS)

    EQ-5D VAS was a participant rated questionnaire to assess health-related quality of life in terms of a single index value. It was a visual analogue scale that ranged from 0 (minimum) to 100 (maximum), with higher scores indicating a better health condition.

    Time frame: Baseline, Month 6, 12, 24, 36, 48

  23. Number of Participants Who Answered Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU)

    Ps-HCRU was a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. In the first section, it assessed direct costs associated with healthcare resource use which included participant's interactions with healthcare providers such as general practitioners, dermatologists, cardiologists, gastroenterologists, psychiatrists, surgeons and nurses. When taking the evening dose of tofacitinib, participants were asked to answer the Ps-HCRU questionnaire only if they had an interaction with a healthcare provider or their work was impacted by psoriasis on that specified day. In this outcome measure, number of participants who answered Ps-HCRU at any specified visits were reported.

    Time frame: Baseline, Month 1, 3, 6, 12, 24, 36, 48

07

Results

Posted Jun 26, 2017

Participant flow

Participant flow — Overall Study
MilestoneTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Started2281586
Completed00
Not completed2281586
Withdrew: Withdrawn due to pregnancy122
Withdrew: Study terminated by sponsor978349
Withdrew: Protocol violation4312
Withdrew: Withdrawal by subject19950
Withdrew: Medication error10
Withdrew: Lost to follow-up12523
Withdrew: Insufficient clinical response42329
Withdrew: Adverse event30078
Withdrew: Death175
Withdrew: Ongoing134
Withdrew: Other unspecified17034

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 4 weeks after last dose (up to 67 months) that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.

Time frame:
Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
AEs1876490
SAEs30488
PrimaryNumber of Adverse Events (AEs) by Severity

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories: a) mild: AEs did not interfere with participant's usual function; b) moderate: AEs interfered to some extent with participant's usual function; c) severe: AEs interfered significantly with participant's usual function.

Time frame:
Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Reported as:
Number · adverse events
Number of Adverse Events (AEs) by Severity
adverse eventsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Mild53541749
Moderate3268766
Severe410136
PrimaryNumber of Participants With Laboratory Abnormalities

Abnormality criteria: hematology (hemoglobin, hematocrit, red blood cell \<0.8\*lower limit of normal \[LLN\]; reticulocyte\<0.5\*LLN,\>1.5\*ULN; platelets\<0.5\*LLN,\>1.75\* upper limit of normal \[ULN\]; WBC\<0.6\*LLN, \>1.5\*ULN; lymphocytes, neutrophils, basophils, eosinophils, monocytes\<0.8\*LLN; \>1.2\*ULN; coagulation (prothrombin \[PT\], PT ratio\>1.1\*ULN) liver function (bilirubin\>1.5\*ULN, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma GT\>0.3\*ULN, protein, albumin\<0.8\*LLN; \>1.2\*ULN, globulin\<0.5\*LLN; \>1.5\*ULN); renal function (blood urea nitrogen, creatinine\>1.3\*ULN); electrolytes(sodium\<0.95\* LLN; \>1.05\* ULN, potassium, chloride, calcium, bicarbonate\<0.9\*LLN; \>1.1\*ULN), chemistry (glucose\<0.6\*LLN; \>1.5\* ULN), urinalysis (pH \<4.5;\>8, glucose, ketones, protein, blood, urobilinogen, nitrite, bilirubin, leukocyte esterase\>=1; RBC, WBC\>=20); lipids (cholesterol \[C\], LDL-C \>1.3\*ULN, HDL-C\<0.8\*LLN, triglycerides\>1.3\* ULN), hormones(T4, T3, T4, TSH\<0.8\* LLN; \>1.2\* ULN).

Time frame:
Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Reported as:
Number · participants
Number of Participants With Laboratory Abnormalities
participantsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Number of Participants With Laboratory Abnormalities2203565
PrimaryChange From Baseline in Hemoglobin Level at Month 1
Time frame:
Baseline, Month 1
Reported as:
Mean · gram per deciliter (g/dL)
Change From Baseline in Hemoglobin Level at Month 1
gram per deciliter (g/dL)Tofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline (n =2277, 586)14.64 ± 1.2714.64 ± 1.24
Change at Month 1 (n =2201, 563)-0.24 ± 0.83-0.32 ± 0.86
PrimaryChange From Baseline in Hemoglobin Level at Month 3
Time frame:
Baseline, Month 3
Reported as:
Mean · g/dL
Change From Baseline in Hemoglobin Level at Month 3
g/dLTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Change From Baseline in Hemoglobin Level at Month 3-0.27 ± 0.85-0.39 ± 0.83
PrimaryChange From Baseline in Hemoglobin Level at Month 6
Time frame:
Baseline, Month 6
Reported as:
Mean · g/dL
Change From Baseline in Hemoglobin Level at Month 6
g/dLTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Change From Baseline in Hemoglobin Level at Month 6-0.27 ± 0.88-0.30 ± 0.87
PrimaryChange From Baseline in Hemoglobin Level at Month 12
Time frame:
Baseline, Month 12
Reported as:
Mean · g/dL
Change From Baseline in Hemoglobin Level at Month 12
g/dLTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Change From Baseline in Hemoglobin Level at Month 12-0.34 ± 0.93-0.30 ± 0.90
PrimaryChange From Baseline in Hemoglobin Level at Month 24
Time frame:
Baseline, Month 24
Reported as:
Mean · g/dL
Change From Baseline in Hemoglobin Level at Month 24
g/dLTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Change From Baseline in Hemoglobin Level at Month 24-0.30 ± 0.96-0.29 ± 0.89
PrimaryChange From Baseline in Hemoglobin Level at Month 36
Time frame:
Baseline, Month 36
Reported as:
Mean · g/dL
Change From Baseline in Hemoglobin Level at Month 36
g/dLTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Change From Baseline in Hemoglobin Level at Month 36-0.32 ± 0.93-0.37 ± 0.88
PrimaryChange From Baseline in Hemoglobin Level at Month 48
Time frame:
Baseline, Month 48
Reported as:
Mean · g/dL
Change From Baseline in Hemoglobin Level at Month 48
g/dLTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Change From Baseline in Hemoglobin Level at Month 48-0.35 ± 0.97-0.43 ± 0.94
PrimaryChange From Baseline in Lymphocyte and Neutrophil Count at Month 1
Time frame:
Baseline, Month 1
Reported as:
Mean · 1000 cells/mm^3
Change From Baseline in Lymphocyte and Neutrophil Count at Month 1
1000 cells/mm^3Tofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline: Lymphocyte Count (n =2275, 586)1.76 ± 0.571.80 ± 0.56
Baseline: Neutrophil Count (n =2275, 586)4.74 ± 1.684.55 ± 1.70
Change at Month 1: Lymphocyte Count (n =2182, 559)0.07 ± 0.520.11 ± 0.56
Change at Month 1: Neutrophil Count (n =2182, 559)-0.37 ± 1.65-0.48 ± 1.58
PrimaryChange From Baseline in Lymphocyte and Neutrophil Count at Month 3
Time frame:
Baseline, Month 3
Reported as:
Mean · 1000 cells/mm^3
Change From Baseline in Lymphocyte and Neutrophil Count at Month 3
1000 cells/mm^3Tofacitinib 10 mgTofacitinib 5 mg or 10 mg
Lymphocyte count-0.00 ± 0.520.02 ± 0.52
Neutrophil Count-0.28 ± 1.63-0.28 ± 1.60
PrimaryChange From Baseline in Lymphocyte and Neutrophil Count at Month 6
Time frame:
Baseline, Month 6
Reported as:
Mean · 1000 cells/mm^3
Change From Baseline in Lymphocyte and Neutrophil Count at Month 6
1000 cells/mm^3Tofacitinib 10 mgTofacitinib 5 mg or 10 mg
Lymphocyte Count-0.11 ± 0.51-0.05 ± 0.51
Neutrophil Count-0.25 ± 1.61-0.22 ± 1.64
PrimaryChange From Baseline in Lymphocyte and Neutrophil Count at Month 12
Time frame:
Baseline, Month 12
Reported as:
Mean · 1000 cells/mm^3
Change From Baseline in Lymphocyte and Neutrophil Count at Month 12
1000 cells/mm^3Tofacitinib 10 mgTofacitinib 5 mg or 10 mg
Lymphocyte Count-0.21 ± 0.52-0.16 ± 0.48
Neutrophil Count-0.23 ± 1.61-0.18 ± 1.58
PrimaryChange From Baseline in Lymphocyte and Neutrophil Count at Month 24
Time frame:
Baseline, Month 24
Reported as:
Mean · 1000 cells/mm^3
Change From Baseline in Lymphocyte and Neutrophil Count at Month 24
1000 cells/mm^3Tofacitinib 10 mgTofacitinib 5 mg or 10 mg
Lymphocyte Count-0.28 ± 0.52-0.18 ± 0.54
Neutrophil Count-0.19 ± 1.69-0.02 ± 1.59
PrimaryChange From Baseline in Lymphocyte and Neutrophil Count at Month 36
Time frame:
Baseline, Month 36
Reported as:
Mean · 1000 cells/mm^3
Change From Baseline in Lymphocyte and Neutrophil Count at Month 36
1000 cells/mm^3Tofacitinib 10 mgTofacitinib 5 mg or 10 mg
Lymphocyte Count-0.35 ± 0.55-0.24 ± 0.51
Neutrophil Count-0.26 ± 1.61-0.11 ± 1.68
PrimaryChange From Baseline in Lymphocyte and Neutrophil Count at Month 48
Time frame:
Baseline, Month 48
Reported as:
Mean · 1000 cells/mm^3
Change From Baseline in Lymphocyte and Neutrophil Count at Month 48
1000 cells/mm^3Tofacitinib 10 mgTofacitinib 5 mg or 10 mg
Lymphocyte Count-0.42 ± 0.52-0.27 ± 0.46
Neutrophil Count-0.28 ± 1.70-0.07 ± 1.49
PrimaryChange From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 1
Time frame:
Baseline, Month 1
Reported as:
Mean · milligram per deciliter (mg/dL)
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 1
milligram per deciliter (mg/dL)Tofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline: Creatinine (n =2278, 586)0.90 ± 0.170.88 ± 0.16
Baseline: LDL-C (n =2253, 585)114.14 ± 32.53115.00 ± 35.03
Baseline: HDL-C (n =2277, 586)49.05 ± 13.9351.87 ± 17.33
Baseline: TC (n =2277, 586)192.11 ± 38.10194.96 ± 39.79
Change at Month 1: Creatinine (n =2204, 563)0.03 ± 0.100.02 ± 0.10
Change at Month 1: LDL-C (n =2125, 546)11.49 ± 28.7711.55 ± 29.55
Change at Month 1: HDL-C (n =2203, 562)8.19 ± 9.898.63 ± 10.50
Change at Month 1: TC (n =2203, 562)21.12 ± 34.0822.65 ± 34.36
PrimaryChange From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 3
Time frame:
Baseline, Month 3
Reported as:
Mean · mg/dL
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 3
mg/dLTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Creatinine (n =2211, 573)0.04 ± 0.210.03 ± 0.10
LDL-C (n =2130, 559)11.97 ± 29.7710.44 ± 32.72
HDL-C (n =2204, 573)7.69 ± 10.237.96 ± 10.33
TC (n =2203, 573)21.52 ± 35.6321.06 ± 38.34
PrimaryChange From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 6
Time frame:
Baseline, Month 6
Reported as:
Mean · mg/dL
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 6
mg/dLTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Creatinine (n =2057, 564)0.03 ± 0.110.03 ± 0.10
LDL-C (n =1983, 553)11.44 ± 30.108.74 ± 33.22
HDL-C (n =2056, 564)7.68 ± 10.338.19 ± 11.60
TC (n =2057, 564)20.91 ± 35.9419.17 ± 39.06
PrimaryChange From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 12
Time frame:
Baseline, Month 12
Reported as:
Mean · mg/dL
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 12
mg/dLTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Creatinine (n =1777, 533)0.04 ± 0.120.04 ± 0.12
LDL-C (n =1728, 521)11.31 ± 31.459.65 ± 32.87
HDL-C (n =1776, 531)8.13 ± 10.486.88 ± 11.15
TC (n =1776, 531)21.20 ± 39.1516.97 ± 37.84
PrimaryChange From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 24
Time frame:
Baseline, Month 24
Reported as:
Mean · mg/dL
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 24
mg/dLTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Creatinine (n =1398, 450)0.05 ± 0.110.04 ± 0.11
LDL-C (n =1353, 435)11.35 ± 35.3310.13 ± 35.67
HDL-C (n =1397, 450)9.02 ± 11.627.55 ± 11.94
TC (n =1398, 450)21.74 ± 41.0519.22 ± 39.69
PrimaryChange From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 36
Time frame:
Baseline, Month 36
Reported as:
Mean · mg/dL
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 36
mg/dLTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Creatinine (n =1122, 384)0.05 ± 0.120.04 ± 0.15
LDL-C (n =1085, 375)10.11 ± 35.837.25 ± 37.41
HDL-C (n =1119, 384)8.80 ± 11.596.39 ± 11.91
TC (n =1119, 384)20.20 ± 41.2815.55 ± 43.59
PrimaryChange From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 48
Time frame:
Baseline, Month 48
Reported as:
Mean · mg/dL
Change From Baseline in Creatinine, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C) and Total Cholesterol (TC) Levels at Month 48
mg/dLTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Creatinine (n =417, 127)0.04 ± 0.120.04 ± 0.11
LDL-C (n =402, 123)12.98 ± 36.896.61 ± 34.66
HDL-C (n =417, 127)8.62 ± 11.368.19 ± 12.72
TC (n =417, 127)24.99 ± 43.3516.36 ± 40.99
PrimaryChange From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 1
Time frame:
Baseline, Month 1
Reported as:
Mean · international unit per liter (IU/L)
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 1
international unit per liter (IU/L)Tofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline: AST (n =2278, 586)24.02 ± 12.2224.66 ± 10.36
Baseline: ALT (n =2278, 586)28.47 ± 17.2928.17 ± 16.56
Change at Month 1: AST (n =2198, 564)3.48 ± 15.394.07 ± 12.01
Change at Month 1: ALT (n =2199, 564)4.07 ± 19.044.84 ± 17.50
PrimaryChange From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 3
Time frame:
Baseline, Month 3
Reported as:
Mean · IU/L
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 3
IU/LTofacitinib 10 mgTofacitinib 5 mg or 10 mg
AST (n =2200, 573)4.09 ± 17.755.65 ± 16.37
ALT (n =2201, 573)4.86 ± 18.526.86 ± 20.80
PrimaryChange From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 6
Time frame:
Baseline, Month 6
Reported as:
Mean · IU/L
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 6
IU/LTofacitinib 10 mgTofacitinib 5 mg or 10 mg
AST (n =2052, 564)4.50 ± 15.605.07 ± 14.90
ALT (n =2054, 564)5.98 ± 19.006.15 ± 18.40
PrimaryChange From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 12
Time frame:
Baseline, Month 12
Reported as:
Mean · IU/L
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 12
IU/LTofacitinib 10 mgTofacitinib 5 mg or 10 mg
AST (n =1772, 531)4.88 ± 16.637.29 ± 22.70
ALT (n =1774, 532)6.68 ± 23.128.91 ± 25.21
PrimaryChange From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 24
Time frame:
Baseline, Month 24
Reported as:
Mean · IU/L
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 24
IU/LTofacitinib 10 mgTofacitinib 5 mg or 10 mg
AST (n =1397, 450)4.10 ± 14.646.77 ± 15.74
ALT (n =1398, 450)5.31 ± 19.377.56 ± 18.93
PrimaryChange From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 36
Time frame:
Baseline, Month 36
Reported as:
Mean · IU/L
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 36
IU/LTofacitinib 10 mgTofacitinib 5 mg or 10 mg
AST5.38 ± 20.685.32 ± 15.65
ALT5.46 ± 20.616.56 ± 22.43
PrimaryChange From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 48
Time frame:
Baseline, Month 48
Reported as:
Mean · IU/L
Change From Baseline in Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) Levels at Month 48
IU/LTofacitinib 10 mgTofacitinib 5 mg or 10 mg
AST (n =416, 127)4.49 ± 14.058.40 ± 26.41
ALT (n =417, 127)4.92 ± 27.116.92 ± 20.98
PrimaryNumber of Participants With Clinically Significant Change From Baseline in Physical Examination

Physical examinations included: general appearance; skin, head, eyes, ears, nose and throat; heart; lungs; abdomen; lower extremities (for the presence of peripheral edema) and lymph nodes. Clinical significance of change from baseline values in physical examination was based on investigator's discretion.

Time frame:
Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Reported as:
Number · participants
Number of Participants With Clinically Significant Change From Baseline in Physical Examination
participantsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Number of Participants With Clinically Significant Change From Baseline in Physical Examination683191
PrimaryNumber of Participants With Vital Sign Abnormalities

Criteria for abnormalities in vital signs included: Systolic blood pressure (SBP): less than (\<) 90 millimeter of mercury (mmHg) and maximum increase from baseline (IFB) of greater than or equal to (\>=) 30 mmHg; diastolic blood pressure (DBP): \<50 and greater than (\>) 120 mmHg and maximum IFB of \>=20 mmHg; heart rate: \<40 and \>120 beats per minute.

Time frame:
Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Reported as:
Number · participants
Number of Participants With Vital Sign Abnormalities
participantsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
SBP (n =2271, 577)126
DBP (n =2271, 577)121
Heart Rate (n =2271, 577)31
Maximum IFB in SBP (n =2267, 577)18765
Maximum IFB in DBP (n =2267, 577)22174
PrimaryChange From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 1
Time frame:
Baseline, Month 1
Reported as:
Mean · millimeter of mercury (mmHg)
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 1
millimeter of mercury (mmHg)Tofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline: Systolic BP (n =2277, 586)126.07 ± 14.03126.24 ± 14.12
Baseline: Diastolic BP (n =2277, 586)79.64 ± 9.4278.88 ± 9.27
Change at Month 1: Systolic BP (n =2210, 564)-0.43 ± 11.83-1.31 ± 11.55
Change at Month 1: Diastolic BP (n =2210, 564)-0.03 ± 8.420.22 ± 8.45
PrimaryChange From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 3
Time frame:
Baseline, Month 3
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 3
mmHgTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Systolic BP-0.16 ± 11.97-0.95 ± 11.85
Diastolic BP-0.26 ± 8.560.05 ± 8.52
PrimaryChange From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 6
Time frame:
Baseline, Month 6
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 6
mmHgTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Systolic BP0.22 ± 12.18-0.15 ± 12.48
Diastolic BP-0.05 ± 8.870.55 ± 8.74
PrimaryChange From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 12
Time frame:
Baseline, Month 12
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 12
mmHgTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Systolic BP0.42 ± 11.97-0.20 ± 12.51
Diastolic BP0.23 ± 8.890.10 ± 9.10
PrimaryChange From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 24
Time frame:
Baseline, Month 24
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 24
mmHgTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Systolic BP0.84 ± 13.00-0.07 ± 13.02
Diastolic BP0.36 ± 9.450.35 ± 8.85
PrimaryChange From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 36
Time frame:
Baseline, Month 36
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 36
mmHgTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Systolic BP0.52 ± 13.150.10 ± 13.92
Diastolic BP0.33 ± 9.33-0.06 ± 9.24
PrimaryChange From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 48
Time frame:
Baseline, Month 48
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 48
mmHgTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Systolic BP2.35 ± 13.451.13 ± 15.18
Diastolic BP0.97 ± 9.520.87 ± 9.80
PrimaryChange From Baseline in Heart Rate at Month 1
Time frame:
Baseline, Month 1
Reported as:
Mean · beats per minute
Change From Baseline in Heart Rate at Month 1
beats per minuteTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline (n =2277, 586)71.81 ± 9.6771.46 ± 9.93
Change at Month 1 (n =2210, 563)-0.82 ± 9.16-1.23 ± 9.03
PrimaryChange From Baseline in Heart Rate at Month 3
Time frame:
Baseline, Month 3
Reported as:
Mean · beats per minute
Change From Baseline in Heart Rate at Month 3
beats per minuteTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Change From Baseline in Heart Rate at Month 3-0.57 ± 9.35-0.32 ± 9.19
PrimaryChange From Baseline in Heart Rate at Month 6
Time frame:
Baseline, Month 6
Reported as:
Mean · beats per minute
Change From Baseline in Heart Rate at Month 6
beats per minuteTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Change From Baseline in Heart Rate at Month 6-0.73 ± 9.65-1.05 ± 9.18
PrimaryChange From Baseline in Heart Rate at Month 12
Time frame:
Baseline, Month 12
Reported as:
Mean · beats per minute
Change From Baseline in Heart Rate at Month 12
beats per minuteTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Change From Baseline in Heart Rate at Month 12-1.13 ± 9.66-1.14 ± 9.07
PrimaryChange From Baseline in Heart Rate at Month 24
Time frame:
Baseline, Month 24
Reported as:
Mean · beats per minute
Change From Baseline in Heart Rate at Month 24
beats per minuteTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Change From Baseline in Heart Rate at Month 24-1.07 ± 9.91-0.94 ± 8.89
PrimaryChange From Baseline in Heart Rate at Month 36
Time frame:
Baseline, Month 36
Reported as:
Mean · beats per minute
Change From Baseline in Heart Rate at Month 36
beats per minuteTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Change From Baseline in Heart Rate at Month 36-1.38 ± 9.81-1.00 ± 9.26
PrimaryChange From Baseline in Heart Rate at Month 48
Time frame:
Baseline, Month 48
Reported as:
Mean · beats per minute
Change From Baseline in Heart Rate at Month 48
beats per minuteTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Change From Baseline in Heart Rate at Month 48-0.91 ± 10.64-0.64 ± 10.64
PrimaryNumber of Participants With Electrocardiogram (ECG) Abnormalities

Criteria for ECG abnormality: PR interval \>=300 milliseconds (msec); QT interval \>=500 msec; QTcB (Bazett's Correction) and QTcF (Fridericia's Correction) 450 to \<480 msec, 480 to \<500 msec and \>=500 msec.

Time frame:
Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Reported as:
Number · participants
Number of Participants With Electrocardiogram (ECG) Abnormalities
participantsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Number of Participants With Electrocardiogram (ECG) Abnormalities72
PrimaryChange From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 6
Time frame:
Baseline, Month 6
Reported as:
Mean · milliseconds (msec)
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 6
milliseconds (msec)Tofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline: QRS Complex (n =2264, 583)92.88 ± 9.1292.31 ± 9.75
Baseline: PR Interval (n =2258, 583)162.32 ± 21.32158.91 ± 20.62
Baseline: QT Interval (n =2264, 583)392.39 ± 29.12395.75 ± 29.70
Baseline: QTcB Interval (n =2264, 583)415.70 ± 23.83416.91 ± 23.04
Baseline: QTcF Interval (n =2264, 583)407.48 ± 20.74409.42 ± 20.11
Baseline: RR Interval (n =2264, 583)901.27 ± 145.58911.59 ± 150.35
Change at Month 6: QRS Complex (n =1995, 550)1.51 ± 8.282.01 ± 7.50
Change at Month 6: PR Interval (n =1986, 549)2.46 ± 13.792.76 ± 14.81
Change at Month 6: QT Interval (n =1995, 550)2.25 ± 24.492.52 ± 24.39
Change at Month 6: QTcB Interval (n =1995, 550)-0.84 ± 20.49-1.38 ± 20.31
Change at Month 6: QTcF Interval (n =1995, 550)0.23 ± 17.14-0.03 ± 17.68
Change at Month 6: RR Interval (n =1995, 550)14.35 ± 130.9118.77 ± 123.49
PrimaryChange From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 12
Time frame:
Baseline, Month 12
Reported as:
Mean · msec
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 12
msecTofacitinib 10 mgTofacitinib 5 mg or 10 mg
QRS Complex (n =1726, 516)1.89 ± 7.932.11 ± 7.53
PR Interval (n =1717, 515)2.80 ± 14.323.21 ± 14.31
QT Interval (n =1726, 516)2.49 ± 23.262.69 ± 23.00
QTcB Interval (n =1726, 516)-1.04 ± 20.63-1.09 ± 20.83
QTcF Interval (n =1726, 516)0.16 ± 16.710.23 ± 17.20
RR Interval (n =1727, 516)15.94 ± 130.6017.55 ± 128.16
PrimaryChange From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 24
Time frame:
Baseline, Month 24
Reported as:
Mean · msec
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 24
msecTofacitinib 10 mgTofacitinib 5 mg or 10 mg
QRS Complex (n =1352, 432)2.00 ± 8.552.42 ± 9.13
PR Interval (n =1346, 432)3.49 ± 14.553.81 ± 14.67
QT Interval (n =1352, 432)3.93 ± 24.932.28 ± 24.80
QTcB Interval (n =1352, 431)0.15 ± 20.770.78 ± 21.06
QTcF Interval (n =1352, 431)1.47 ± 16.861.25 ± 17.72
RR Interval (n =1352, 432)17.70 ± 139.478.66 ± 135.06
PrimaryChange From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 36
Time frame:
Baseline, Month 36
Reported as:
Mean · msec
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 36
msecTofacitinib 10 mgTofacitinib 5 mg or 10 mg
QRS Complex (n =845, 283)1.75 ± 8.471.85 ± 10.37
PR Interval (n =840, 282)4.18 ± 14.503.25 ± 15.50
QT Interval (n =844, 283)4.31 ± 24.932.52 ± 22.63
QTcB Interval (n =844, 283)0.44 ± 21.29-0.01 ± 22.21
QTcF Interval (n =844, 283)1.79 ± 17.570.84 ± 17.63
RR Interval (n =845, 283)18.24 ± 136.4415.14 ± 131.42
PrimaryChange From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 48
Time frame:
Baseline, Month 48
Reported as:
Mean · msec
Change From Baseline in QRS Complex, PR, QT, QTcB, QTcF and RR Interval at Month 48
msecTofacitinib 10 mgTofacitinib 5 mg or 10 mg
QRS Complex (n =126, 55)2.37 ± 10.171.31 ± 5.37
PR Interval (n =126, 55)6.26 ± 12.581.98 ± 13.20
QT Interval (n =126, 55)6.43 ± 24.051.69 ± 23.43
QTcB Interval (n =125, 55)3.42 ± 20.11-2.00 ± 22.64
QTcF Interval (n =125, 55)4.55 ± 15.84-0.87 ± 19.38
RR Interval (n =126, 55)15.69 ± 143.0620.78 ± 119.61
PrimaryNumber of Participants With Adjudicated Cardiovascular Events

Adjudicated cardiovascular events were assessed by adjudication committee as independent reviewers based on event documentation including: hospital discharge summaries, operative reports, clinic notes, ECGs, diagnostic enzymes, results of other diagnostic tests, autopsy reports and death certificate information; as applicable.

Time frame:
Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Reported as:
Number · participants
Number of Participants With Adjudicated Cardiovascular Events
participantsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Number of Participants With Adjudicated Cardiovascular Events3213
PrimaryNumber of Participants With Malignancy Events

Malignancy events included lymphoma, and demyelinating neurologic events. Biopsies collected for malignancy events were submitted to the central laboratory for pathologist over-read.

Time frame:
Baseline up to 4 weeks after last dose of study drug (up to a maximum of 67 months)
Reported as:
Number · participants
Number of Participants With Malignancy Events
participantsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Number of Participants With Malignancy Events8726
SecondaryPercentage of Participants Achieving Physician Global Assessment (PGA) Response of 'Clear' or 'Almost Clear'

The PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema (E), induration (I), and scaling (S) across all psoriatic lesions in participants. The severity rating scores (Erythema: 0= no evidence of erythema to 4= dark, deep red; Induration: 0= no evidence of plaque elevation to 4= marked plaque elevation, hard/sharp borders; Scaling: 0= no evidence of scaling to 4= thick, coarse scale predominates) were summed (E + I + S = total) and the average (total/3) was taken. The total average was rounded to the nearest whole number score to determine the PGA. The 5-point scale for PGA was: 0= clear; 1= almost clear; 2= mild; 3= moderate; 4= severe, where higher score indicated more severity of psoriasis. Percentage of participants with response of 'clear' (score of '0') and 'almost clear' (score of '1') were reported.

Time frame:
Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Physician Global Assessment (PGA) Response of 'Clear' or 'Almost Clear'
percentage of participantsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Month 1 (n =2196, 563)50.36 (48.27 to 52.46)77.80 (74.36 to 81.23)
Month 3 (n =2200, 571)54.86 (52.78 to 56.94)85.29 (82.38 to 88.19)
Month 6 (n =2052, 564)54.97 (52.82 to 57.12)82.09 (78.93 to 85.26)
Month 12 (n =1776, 532)54.79 (52.47 to 57.10)75.19 (71.52 to 78.86)
Month 24 (n =1397, 448)54.62 (52.01 to 57.23)79.46 (75.72 to 83.20)
Month 36 (n =1123, 385)57.35 (54.45 to 60.24)76.36 (72.12 to 80.61)
Month 48 (n =422, 126)48.58 (43.81 to 53.35)77.78 (70.52 to 85.04)
SecondaryPercentage of Participants Achieving Greater Than or Equal to (>=) 75 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores

PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=75 percent (%) reduction from baseline in PASI scores were reported.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Greater Than or Equal to (>=) 75 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores
percentage of participantsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Month 1 (n =2194, 555)51.96 (49.87 to 54.05)71.89 (68.15 to 75.63)
Month 3 (n =2200, 566)58.45 (56.40 to 60.51)84.45 (81.47 to 87.44)
Month 6 (n =2048, 557)61.67 (59.56 to 63.78)86.00 (83.11 to 88.88)
Month 12 (n =1775, 525)65.24 (63.02 to 67.45)80.76 (77.39 to 84.13)
Month 24 (n =1393, 445)67.26 (64.80 to 69.73)84.94 (81.62 to 88.27)
Month 36 (n =1118, 380)70.75 (68.08 to 73.42)83.95 (80.26 to 87.64)
Month 48 (n =422, 124)64.93 (60.38 to 69.48)83.06 (76.46 to 89.67)
SecondaryPsoriasis Area and Severity Index (PASI) Scores

PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
Psoriasis Area and Severity Index (PASI) Scores
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline (n =2266, 585)21.85 ± 9.4819.05 ± 8.89
Month 1 (n =2198, 561)6.60 ± 7.143.09 ± 4.81
Month 3 (n =2205, 572)5.64 ± 6.331.95 ± 3.25
Month 6 (n =2051, 563)5.31 ± 6.311.90 ± 3.25
Month 12 (n =1779, 531)4.72 ± 5.292.38 ± 3.57
Month 24 (n =1397, 449)4.41 ± 5.081.90 ± 2.65
Month 36 (n =1121, 384)3.91 ± 4.662.19 ± 3.23
Month 48 (n =422, 126)4.75 ± 5.371.85 ± 2.31
SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Scores at Month 1, 3, 6, 12, 24, 36 and 48

PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores at Month 1, 3, 6, 12, 24, 36 and 48
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Month 1 (n =2195, 561)-15.26 ± 9.96-16.00 ± 9.57
Month 3 (n =2201, 572)-16.18 ± 9.73-16.99 ± 9.27
Month 6 (n =2049, 563)-16.56 ± 9.54-17.03 ± 9.16
Month 12 (n =1776, 531)-17.01 ± 9.33-16.45 ± 9.04
Month 24 (n =1394, 449)-17.25 ± 9.35-16.67 ± 8.70
Month 36 (n =1119, 384)-17.44 ± 9.23-16.49 ± 8.81
Month 48 (n =422, 126)-16.16 ± 8.61-15.47 ± 9.04
SecondaryPsoriasis Area and Severity Index (PASI) Component Scores: Erythema

PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Erythema was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
Psoriasis Area and Severity Index (PASI) Component Scores: Erythema
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline: Head/Neck (n =2266, 585)2.26 ± 0.992.13 ± 1.08
Month 1: Head/Neck (n =2198, 561)0.82 ± 0.960.47 ± 0.81
Month 3: Head/Neck (n =2205, 572)0.76 ± 0.950.34 ± 0.65
Month 6: Head/Neck (n =2051, 563)0.75 ± 0.950.42 ± 0.75
Month 12: Head/Neck (n =1779, 531)0.70 ± 0.920.49 ± 0.82
Month 24: Head/Neck (n =1397, 449)0.66 ± 0.930.47 ± 0.75
Month 36: Head/Neck (n =1121, 384)0.57 ± 0.880.48 ± 0.79
Month 48: Head/Neck (n =422, 126)0.70 ± 0.930.34 ± 0.69
Baseline: Upper Limbs (n =2266, 585)2.82 ± 0.742.68 ± 0.86
Month 1: Upper Limbs (n =2198, 561)1.29 ± 0.980.71 ± 0.86
Month 3: Upper Limbs (n =2205, 572)1.23 ± 1.000.57 ± 0.79
Month 6: Upper Limbs (n =2051, 563)1.20 ± 1.010.58 ± 0.83
Month 12: Upper Limbs (n =1779, 531)1.16 ± 1.010.74 ± 0.95
Month 24: Upper Limbs (n =1397, 449)1.13 ± 1.030.61 ± 0.85
Month 36: Upper Limbs (n =1121, 384)1.06 ± 1.010.68 ± 0.86
Month 48: Upper Limbs (n =422, 126)1.18 ± 1.030.58 ± 0.84
Baseline: Trunk (n =2266, 585)2.83 ± 0.832.73 ± 0.94
Month 1: Trunk (n =2198, 561)1.18 ± 1.110.62 ± 0.92
Month 3: Trunk (n =2205, 572)1.06 ± 1.090.41 ± 0.73
Month 6: Trunk (n =2051, 563)1.03 ± 1.090.41 ± 0.79
Month 12: Trunk (n =1779, 531)0.99 ± 1.080.51 ± 0.89
Month 24: Trunk (n =1397, 449)0.96 ± 1.080.49 ± 0.84
Month 36: Trunk (n =1121, 384)0.86 ± 1.060.53 ± 0.90
Month 48: Trunk (n =422, 126)1.00 ± 1.100.50 ± 0.86
Baseline: Lower Limbs (n =2266, 585)3.10 ± 0.702.94 ± 0.89
Month 1: Lower Limbs (n =2198, 561)1.37 ± 1.090.79 ± 0.95
Month 3: Lower Limbs (n =2205, 572)1.24 ± 1.080.58 ± 0.84
Month 6: Lower Limbs (n =2051, 563)1.20 ± 1.110.52 ± 0.81
Month 12: Lower Limbs (n =1779, 531)1.17 ± 1.100.69 ± 0.98
Month 24: Lower Limbs (n =1397, 449)1.15 ± 1.110.59 ± 0.90
Month 36: Lower Limbs (n =1121, 384)1.07 ± 1.110.67 ± 0.96
Month 48: Lower Limbs (n =422, 126)1.20 ± 1.110.61 ± 0.91
SecondaryPsoriasis Area and Severity Index (PASI) Component Scores: Induration

PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Induration was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
Psoriasis Area and Severity Index (PASI) Component Scores: Induration
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline: Head/Neck (n =2266, 585)1.97 ± 1.011.88 ± 1.10
Month 1: Head/Neck (n =2198, 561)0.65 ± 0.850.35 ± 0.73
Month 3: Head/Neck (n =2205, 572)0.60 ± 0.840.26 ± 0.56
Month 6: Head/Neck (n =2051, 563)0.59 ± 0.860.31 ± 0.67
Month 12: Head/Neck (n =1779, 531)0.55 ± 0.810.38 ± 0.71
Month 24: Head/Neck (n =1397, 449)0.53 ± 0.820.37 ± 0.68
Month 36: Head/Neck (n =1121, 384)0.46 ± 0.770.37 ± 0.68
Month 48: Head/Neck (n =422, 126)0.60 ± 0.850.26 ± 0.60
Baseline: Upper Limbs (n =2266, 585)2.64 ± 0.772.50 ± 0.93
Month 1: Upper Limbs (n =2198, 561)1.21 ± 0.990.66 ± 0.88
Month 3: Upper Limbs (n =2205, 572)1.17 ± 1.010.53 ± 0.81
Month 6: Upper Limbs (n =2051, 563)1.15 ± 1.020.55 ± 0.85
Month 12: Upper Limbs (n =1779, 531)1.11 ± 1.010.69 ± 0.95
Month 24: Upper Limbs (n =1397, 449)1.08 ± 1.020.53 ± 0.84
Month 36: Upper Limbs (n =1121, 384)1.00 ± 1.010.60 ± 0.82
Month 48: Upper Limbs (n =422, 126)1.09 ± 1.000.50 ± 0.75
Baseline: Trunk (n =2266, 585)2.57 ± 0.862.51 ± 1.01
Month 1: Trunk (n =2198, 561)1.02 ± 1.040.52 ± 0.86
Month 3: Trunk (n =2205, 572)0.91 ± 1.020.34 ± 0.68
Month 6: Trunk (n =2051, 563)0.88 ± 1.000.34 ± 0.71
Month 12: Trunk (n =1779, 531)0.87 ± 1.000.42 ± 0.77
Month 24: Trunk (n =1397, 449)0.82 ± 0.980.39 ± 0.73
Month 36: Trunk (n =1121, 384)0.75 ± 0.970.43 ± 0.79
Month 48: Trunk (n =422, 126)0.91 ± 1.050.44 ± 0.80
Baseline: Lower Limbs (n =2266, 585)2.85 ± 0.762.77 ± 0.96
Month 1: Lower Limbs (n =2198, 561)1.22 ± 1.040.68 ± 0.95
Month 3: Lower Limbs (n =2205, 572)1.10 ± 1.040.51 ± 0.84
Month 6: Lower Limbs (n =2051, 563)1.08 ± 1.060.47 ± 0.82
Month 12: Lower Limbs (n =1779, 531)1.05 ± 1.030.61 ± 0.94
Month 24: Lower Limbs (n =1397, 449)1.02 ± 1.030.49 ± 0.83
Month 36: Lower Limbs (n =1121, 384)0.95 ± 1.030.57 ± 0.87
Month 48: Lower Limbs (n =422, 126)1.07 ± 1.040.48 ± 0.79
SecondaryPsoriasis Area and Severity Index (PASI) Component Scores: Scaling

PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Scaling was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
Psoriasis Area and Severity Index (PASI) Component Scores: Scaling
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline: Head/Neck (n =2266, 585)2.22 ± 1.082.10 ± 1.11
Month 1: Head/Neck (n =2198, 561)0.75 ± 0.950.42 ± 0.79
Month 3: Head/Neck (n =2205, 572)0.71 ± 0.950.32 ± 0.66
Month 6: Head/Neck (n =2051, 563)0.71 ± 0.970.40 ± 0.77
Month 12: Head/Neck (n =1779, 531)0.67 ± 0.920.48 ± 0.84
Month 24: Head/Neck (n =1397, 449)0.60 ± 0.880.45 ± 0.77
Month 36: Head/Neck (n =1121, 384)0.55 ± 0.880.47 ± 0.79
Month 48: Head/Neck (n =422, 126)0.65 ± 0.930.34 ± 0.72
Baseline: Upper Limbs (n =2266, 585)2.65 ± 0.822.52 ± 0.96
Month 1: Upper Limbs (n =2198, 561)1.22 ± 1.010.69 ± 0.89
Month 3: Upper Limbs (n =2205, 572)1.18 ± 1.040.55 ± 0.80
Month 6: Upper Limbs (n =2051, 563)1.16 ± 1.050.58 ± 0.87
Month 12: Upper Limbs (n =1779, 531)1.12 ± 1.030.72 ± 0.97
Month 24: Upper Limbs (n =1397, 449)1.08 ± 1.030.58 ± 0.84
Month 36: Upper Limbs (n =1121, 384)1.01 ± 1.020.62 ± 0.83
Month 48: Upper Limbs (n =422, 126)1.13 ± 1.090.53 ± 0.79
Baseline: Trunk (n =2266, 585)2.55 ± 0.892.47 ± 1.00
Month 1: Trunk (n =2198, 561)0.97 ± 1.020.50 ± 0.83
Month 3: Trunk (n =2205, 572)0.87 ± 1.000.33 ± 0.64
Month 6: Trunk (n =2051, 563)0.85 ± 0.990.33 ± 0.70
Month 12: Trunk (n =1779, 531)0.83 ± 0.970.40 ± 0.76
Month 24: Trunk (n =1397, 449)0.78 ± 0.950.39 ± 0.72
Month 36: Trunk (n =1121, 384)0.71 ± 0.930.42 ± 0.77
Month 48: Trunk (n =422, 126)0.86 ± 0.990.40 ± 0.78
Baseline: Lower Limbs (n =2266, 585)2.89 ± 0.812.79 ± 1.00
Month 1: Lower Limbs (n =2198, 561)1.23 ± 1.080.70 ± 0.93
Month 3: Lower Limbs (n =2205, 572)1.12 ± 1.080.48 ± 0.78
Month 6: Lower Limbs (n =2051, 563)1.11 ± 1.100.48 ± 0.83
Month 12: Lower Limbs (n =1779, 531)1.07 ± 1.070.64 ± 0.98
Month 24: Lower Limbs (n =1397, 449)1.04 ± 1.060.53 ± 0.84
Month 36: Lower Limbs (n =1121, 384)0.94 ± 1.030.60 ± 0.90
Month 48: Lower Limbs (n =422, 126)1.09 ± 1.090.48 ± 0.76
SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Erythema at Month 1, 3, 6, 12, 24, 36 and 48

PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Erythema was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Erythema at Month 1, 3, 6, 12, 24, 36 and 48
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Month 1: Head/Neck (n =2195, 561)-1.43 ± 1.15-1.66 ± 1.20
Month 3: Head/Neck (n =2201, 572)-1.50 ± 1.18-1.80 ± 1.18
Month 6: Head/Neck (n =2049, 563)-1.52 ± 1.20-1.72 ± 1.21
Month 12: Head/Neck (n =1776, 531)-1.56 ± 1.19-1.64 ± 1.22
Month 24: Head/Neck (n =1394, 449)-1.62 ± 1.19-1.67 ± 1.23
Month 36: Head/Neck (n =1119, 384)-1.72 ± 1.18-1.67 ± 1.20
Month 48: Head/Neck (n =422, 126)-1.55 ± 1.19-1.70 ± 1.13
Month 1: Upper Limbs (n =2195, 561)-1.53 ± 1.12-1.98 ± 1.18
Month 3: Upper Limbs (n =2201, 572)-1.59 ± 1.15-2.12 ± 1.14
Month 6: Upper Limbs (n =2049, 563)-1.62 ± 1.15-2.09 ± 1.13
Month 12: Upper Limbs (n =1776, 531)-1.67 ± 1.15-1.94 ± 1.21
Month 24: Upper Limbs (n =1394, 449)-1.70 ± 1.18-2.05 ± 1.19
Month 36: Upper Limbs (n =1119, 384)-1.78 ± 1.17-2.00 ± 1.18
Month 48: Upper Limbs (n =422, 126)-1.62 ± 1.16-1.90 ± 1.22
Month 1: Trunk (n =2195, 561)-1.65 ± 1.22-2.12 ± 1.26
Month 3: Trunk (n =2201, 572)-1.77 ± 1.24-2.33 ± 1.17
Month 6: Trunk (n =2049, 563)-1.81 ± 1.24-2.32 ± 1.19
Month 12: Trunk (n =1776, 531)-1.86 ± 1.24-2.21 ± 1.25
Month 24: Trunk (n =1394, 449)-1.88 ± 1.25-2.22 ± 1.26
Month 36: Trunk (n =1119, 384)-1.99 ± 1.26-2.18 ± 1.30
Month 48: Trunk (n =422, 126)-1.82 ± 1.22-2.08 ± 1.17
Month 1: Lower Limbs (n =2195, 561)-1.72 ± 1.19-2.16 ± 1.26
Month 3: Lower Limbs (n =2201, 572)-1.87 ± 1.21-2.36 ± 1.21
Month 6: Lower Limbs (n =2049, 563)-1.90 ± 1.22-2.42 ± 1.18
Month 12: Lower Limbs (n =1776, 531)-1.94 ± 1.23-2.24 ± 1.33
Month 24: Lower Limbs (n =1394, 449)-1.95 ± 1.25-2.32 ± 1.24
Month 36: Lower Limbs (n =1119, 384)-2.04 ± 1.23-2.28 ± 1.30
Month 48: Lower Limbs (n =422, 126)-1.87 ± 1.20-2.17 ± 1.21
SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Induration at Month 1, 3, 6, 12, 24, 36 and 48

PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Induration was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Induration at Month 1, 3, 6, 12, 24, 36 and 48
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Month 1: Head/Neck (n =2195, 561)-1.32 ± 1.13-1.53 ± 1.15
Month 3: Head/Neck (n =2201, 572)-1.37 ± 1.17-1.63 ± 1.14
Month 6: Head/Neck (n =2049, 563)-1.40 ± 1.16-1.57 ± 1.18
Month 12: Head/Neck (n =1776, 531)-1.44 ± 1.18-1.49 ± 1.18
Month 24: Head/Neck (n =1394, 449)-1.48 ± 1.17-1.51 ± 1.21
Month 36: Head/Neck (n =1119, 384)-1.55 ± 1.17-1.51 ± 1.15
Month 48: Head/Neck (n =422, 126)-1.35 ± 1.17-1.41 ± 1.10
Month 1: Upper Limbs (n =2195, 561)-1.43 ± 1.14-1.85 ± 1.22
Month 3: Upper Limbs (n =2201, 572)-1.47 ± 1.17-1.97 ± 1.16
Month 6: Upper Limbs (n =2049, 563)-1.49 ± 1.15-1.94 ± 1.19
Month 12: Upper Limbs (n =1776, 531)-1.54 ± 1.14-1.82 ± 1.27
Month 24: Upper Limbs (n =1394, 449)-1.57 ± 1.18-1.97 ± 1.19
Month 36: Upper Limbs (n =1119, 384)-1.65 ± 1.17-1.92 ± 1.18
Month 48: Upper Limbs (n =422, 126)-1.53 ± 1.14-1.83 ± 1.14
Month 1: Trunk (n =2195, 561)-1.55 ± 1.19-2.01 ± 1.26
Month 3: Trunk (n =2201, 572)-1.65 ± 1.22-2.17 ± 1.18
Month 6: Trunk (n =2049, 563)-1.70 ± 1.19-2.18 ± 1.20
Month 12: Trunk (n =1776, 531)-1.71 ± 1.20-2.10 ± 1.24
Month 24: Trunk (n =1394, 449)-1.76 ± 1.19-2.13 ± 1.20
Month 36: Trunk (n =1119, 384)-1.85 ± 1.20-2.09 ± 1.23
Month 48: Trunk (n =422, 126)-1.68 ± 1.17-1.87 ± 1.20
Month 1: Lower Limbs (n =2195, 561)-1.63 ± 1.22-2.09 ± 1.31
Month 3: Lower Limbs (n =2201, 572)-1.75 ± 1.22-2.26 ± 1.24
Month 6: Lower Limbs (n =2049, 563)-1.78 ± 1.23-2.30 ± 1.23
Month 12: Lower Limbs (n =1776, 531)-1.82 ± 1.20-2.17 ± 1.33
Month 24: Lower Limbs (n =1394, 449)-1.85 ± 1.22-2.28 ± 1.24
Month 36: Lower Limbs (n =1119, 384)-1.93 ± 1.21-2.22 ± 1.29
Month 48: Lower Limbs (n =422, 126)-1.77 ± 1.18-2.07 ± 1.24
SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Scaling at Month 1, 3, 6, 12, 24, 36 and 48

PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Scaling was assessed separately for four body areas (head and neck, upper limbs, trunk and lower limbs) on a 5-point scale ranges from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores: Scaling at Month 1, 3, 6, 12, 24, 36 and 48
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Month 1: Head/Neck (n =2195, 561)-1.46 ± 1.19-1.69 ± 1.20
Month 3: Head/Neck (n =2201, 572)-1.51 ± 1.24-1.78 ± 1.19
Month 6: Head/Neck (n =2049, 563)-1.52 ± 1.24-1.70 ± 1.22
Month 12: Head/Neck (n =1776, 531)-1.56 ± 1.25-1.61 ± 1.24
Month 24: Head/Neck (n =1394, 449)-1.63 ± 1.24-1.63 ± 1.27
Month 36: Head/Neck (n =1119, 384)-1.68 ± 1.22-1.64 ± 1.22
Month 48: Head/Neck (n =422, 126)-1.53 ± 1.24-1.58 ± 1.17
Month 1: Upper Limbs (n =2195, 561)-1.44 ± 1.18-1.84 ± 1.24
Month 3: Upper Limbs (n =2201, 572)-1.47 ± 1.20-1.97 ± 1.18
Month 6: Upper Limbs (n =2049, 563)-1.49 ± 1.21-1.94 ± 1.26
Month 12: Upper Limbs (n =1776, 531)-1.52 ± 1.21-1.82 ± 1.30
Month 24: Upper Limbs (n =1394, 449)-1.56 ± 1.22-1.96 ± 1.22
Month 36: Upper Limbs (n =1119, 384)-1.65 ± 1.19-1.93 ± 1.15
Month 48: Upper Limbs (n =422, 126)-1.45 ± 1.19-1.78 ± 1.22
Month 1: Trunk (n =2195, 561)-1.58 ± 1.20-1.98 ± 1.24
Month 3: Trunk (n =2201, 572)-1.67 ± 1.22-2.14 ± 1.14
Month 6: Trunk (n =2049, 563)-1.70 ± 1.19-2.14 ± 1.22
Month 12: Trunk (n =1776, 531)-1.72 ± 1.21-2.08 ± 1.23
Month 24: Trunk (n =1394, 449)-1.77 ± 1.20-2.11 ± 1.19
Month 36: Trunk (n =1119, 384)-1.84 ± 1.20-2.06 ± 1.23
Month 48: Trunk (n =422, 126)-1.62 ± 1.19-1.80 ± 1.18
Month 1: Lower Limbs (n =2195, 561)-1.67 ± 1.24-2.09 ± 1.30
Month 3: Lower Limbs (n =2201, 572)-1.77 ± 1.26-2.30 ± 1.23
Month 6: Lower Limbs (n =2049, 563)-1.79 ± 1.27-2.30 ± 1.25
Month 12: Lower Limbs (n =1776, 531)-1.83 ± 1.26-2.15 ± 1.36
Month 24: Lower Limbs (n =1394, 449)-1.86 ± 1.27-2.25 ± 1.24
Month 36: Lower Limbs (n =1119, 384)-1.97 ± 1.23-2.21 ± 1.26
Month 48: Lower Limbs (n =422, 126)-1.77 ± 1.29-2.11 ± 1.23
SecondaryPercentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores

PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=50% reduction from baseline in PASI scores were reported.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores
percentage of participantsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Month 1 (n =2194, 555)76.53 (74.75 to 78.30)86.67 (83.84 to 89.49)
Month 3 (n =2200, 566)81.59 (79.97 to 83.21)95.05 (93.27 to 96.84)
Month 6 (n =2048, 557)85.64 (84.13 to 87.16)93.90 (91.91 to 95.88)
Month 12 (n =1775, 525)87.66 (86.13 to 89.19)93.14 (90.98 to 95.30)
Month 24 (n =1393, 445)88.87 (87.22 to 90.52)94.61 (92.51 to 96.71)
Month 36 (n =1118, 380)90.97 (89.29 to 92.65)92.63 (90.00 to 95.26)
Month 48 (n =422, 124)88.86 (85.86 to 91.86)97.58 (94.88 to 100.00)
SecondaryPercentage of Participants Achieving Greater Than or Equal to (>=) 90 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores

PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=90% reduction from baseline in PASI scores were reported.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Greater Than or Equal to (>=) 90 Percent Reduction From Baseline in Psoriasis Area and Severity Index (PASI) Scores
percentage of participantsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Month 1 (n =2194, 555)29.99 (28.07 to 31.91)56.04 (51.91 to 60.17)
Month 3 (n =2200, 566)33.73 (31.75 to 35.70)65.37 (61.45 to 69.29)
Month 6 (n =2048, 557)35.21 (33.14 to 37.27)65.89 (61.95 to 69.83)
Month 12 (n =1775, 525)35.94 (33.71 to 38.18)61.71 (57.56 to 65.87)
Month 24 (n =1393, 445)38.33 (35.78 to 40.89)62.02 (57.51 to 66.53)
Month 36 (n =1118, 380)43.02 (40.12 to 45.93)60.53 (55.61 to 65.44)
Month 48 (n =422, 124)34.36 (29.83 to 38.89)58.06 (49.38 to 66.75)
SecondaryPercentage of Participants Achieving Greater Than or Equal to (>=) 125 Percent Increase From Baseline in Psoriasis Area and Severity Index (PASI) Scores

PASI score is the combined assessment of lesion severity (estimated by 3 components: of erythema, induration and scaling) and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Each component of severity, that is, erythema, induration and scaling was assessed separately for four body areas (head and neck \[h\], upper limbs \[u\], trunk \[t\] and lower limbs \[l\]) on a 5-point scale ranging from 0=no involvement, 1=slight, 2=moderate, 3=marked, 4=very marked. Higher score indicates greater severity. Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head and neck: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4. Percentage of participants with \>=125% increase from baseline in PASI scores were reported.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Greater Than or Equal to (>=) 125 Percent Increase From Baseline in Psoriasis Area and Severity Index (PASI) Scores
percentage of participantsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Month 1 (n =2194, 555)0.96 (0.55 to 1.36)1.08 (0.22 to 1.94)
Month 3 (n =2200, 566)1.18 (0.73 to 1.63)0.71 (0.02 to 1.40)
Month 6 (n =2048, 557)1.27 (0.78 to 1.75)0.90 (0.11 to 1.68)
Month 12 (n =1775, 525)0.90 (0.46 to 1.34)1.33 (0.35 to 2.31)
Month 24 (n =1393, 445)0.93 (0.43 to 1.44)0.90 (0.02 to 1.78)
Month 36 (n =1118, 380)0.54 (0.11 to 0.96)1.32 (0.17 to 2.46)
Month 48 (n =422, 124)0.71 (0.00 to 1.51)0.00 (0.00 to 0.00)
SecondaryItch Severity Item (ISI) Scores

ISI assessed severity of itching due to psoriasis. ISI was a single item, horizontal numeric rating scale. Participants were asked to rate their 'severity of itching' due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms '0=no itching' and '10=worst possible itching' at the ends. Higher scores indicated greater severity of itching.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
Itch Severity Item (ISI) Scores
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline (n =2172, 566)5.76 ± 2.915.17 ± 3.00
Month 1 (n =2196, 561)1.88 ± 2.260.92 ± 1.53
Month 3 (n =2197, 572)1.83 ± 2.320.72 ± 1.39
Month 6 (n =2047, 560)1.87 ± 2.330.82 ± 1.51
Month 12 (n =1774, 530)1.79 ± 2.211.08 ± 1.67
Month 24 (n =1394, 449)1.83 ± 2.231.01 ± 1.54
Month 36 (n =1117, 383)1.69 ± 2.121.21 ± 1.72
Month 48 (n =417, 127)1.92 ± 2.301.24 ± 1.74
SecondaryChange From Baseline in Itch Severity Item (ISI) Scores at Month 1, 3, 6, 12, 24, 36 and 48

ISI assessed severity of itching due to psoriasis. ISI was a single item, horizontal numeric rating scale. Participants were asked to rate their 'severity of itching' due to psoriasis over the past 24 hours on a numeric rating scale anchored by the terms '0=no itching' and '10=worst possible itching' at the ends. Higher scores indicated greater severity of itching.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
Change From Baseline in Itch Severity Item (ISI) Scores at Month 1, 3, 6, 12, 24, 36 and 48
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Month 1 (n =2107, 544)-3.88 ± 3.06-4.26 ± 3.07
Month 3 (n =2103, 554)-3.94 ± 3.18-4.44 ± 3.06
Month 6 (n =1958, 543)-3.91 ± 3.20-4.36 ± 3.14
Month 12 (n =1693, 514)-3.90 ± 3.17-4.01 ± 3.30
Month 24 (n =1340, 435)-3.80 ± 3.14-4.11 ± 3.17
Month 36 (n =1078, 372)-3.95 ± 3.18-3.84 ± 3.06
Month 48 (n =411, 126)-4.03 ± 3.19-3.78 ± 3.25
SecondaryDermatology Life Quality Index (DLQI) Scores

The DLQI was a validated, self-administered, 10-item quality-of-life questionnaire that consisted of 10 items that assessed the impact of skin disease on quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Each question was scored on a scale of 0=not at all/not relevant to 3=very much. Response from all of the 10 questions were added to derive the DLQI total scores. Total DLQI scores ranges from 0=not at all to 30=very much, with higher scores indicating greater impairment in quality of life.

Time frame:
Baseline, Month 1, 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
Dermatology Life Quality Index (DLQI) Scores
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline (n =2243, 582)12.73 ± 7.1210.95 ± 6.61
Month 1 (n =2189, 559)4.11 ± 5.232.14 ± 3.43
Month 6 (n =2028, 557)3.68 ± 5.001.67 ± 3.33
Month 12 (n =1751, 528)3.44 ± 4.651.71 ± 2.92
Month 24 (n =1361, 441)3.49 ± 4.711.94 ± 3.29
Month 36 (n =1093, 372)2.97 ± 4.051.98 ± 3.35
Month 48 (n =407, 124)3.20 ± 4.391.81 ± 2.98
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Scores at Month 1, 6, 12, 24, 36 and 48

The DLQI was a validated, self-administered, 10-item quality-of-life questionnaire that consisted of 10 items that assessed the impact of skin disease on quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Each question was scored on a scale of 0=not at all/not relevant to 3=very much. Response from all of the 10 questions were added to derive the DLQI total scores. Total DLQI scores ranges from 0=not at all to 30=very much, with higher scores indicating greater impairment in quality of life.

Time frame:
Baseline, Month 1, 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Scores at Month 1, 6, 12, 24, 36 and 48
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Month 1 (n =2163, 556)-8.61 ± 7.00-8.75 ± 6.56
Month 6 (n =2005, 554)-9.14 ± 7.06-9.22 ± 6.92
Month 12 (n =1730, 525)-9.23 ± 6.91-9.02 ± 6.68
Month 24 (n =1345, 438)-9.08 ± 6.82-8.47 ± 6.43
Month 36 (n =1083, 369)-9.47 ± 6.80-8.46 ± 6.14
Month 48 (n =404, 122)-8.99 ± 6.74-7.78 ± 6.10
Secondary36-Item Short-Form (SF-36) Health Survey Version 2, Acute: Physical Component Summary Scores

The SF-36 questionnaire, version 2, acute was a 36-item generic health status measure. SF-36 evaluated 8 health-related aspects of an individual: physical functioning, role-physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition. Two summary scale scores were computed from the 8 health aspect scores: physical component summary score and mental component summary score. Score range for both summary scales ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition.

Time frame:
Baseline, Month 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
36-Item Short-Form (SF-36) Health Survey Version 2, Acute: Physical Component Summary Scores
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline (n =2233, 580)47.31 ± 9.3848.94 ± 9.12
Month 6 (n =2025, 557)51.78 ± 8.2453.51 ± 7.30
Month 12 (n =1750, 524)51.96 ± 8.1353.58 ± 7.19
Month 24 (n =1362, 442)51.91 ± 7.8053.15 ± 7.32
Month 36 (n =857, 286)52.01 ± 8.0853.05 ± 7.28
Month 48 (n =124, 56)52.93 ± 6.7952.36 ± 8.39
Secondary36-Item Short-Form (SF-36) Health Survey Version 2, Acute: Mental Component Summary Scores

The SF-36 questionnaire, version 2 was a 36-item generic health status measure. SF-36 evaluated 8 health-related aspects of an individual: physical functioning, role-physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition. Two summary scale scores were computed from the 8 health aspect scores: the Physical Component Summary and the Mental Component Summary. Score range for both summary scale ranged from 0 (worst) to 100 (best), with higher scores indicating good health condition.

Time frame:
Baseline, Month 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
36-Item Short-Form (SF-36) Health Survey Version 2, Acute: Mental Component Summary Scores
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline (n =2233, 580)43.51 ± 11.9843.96 ± 11.23
Month 6 (n =2025, 557)48.86 ± 10.0250.03 ± 9.14
Month 12 (n =1750, 524)49.10 ± 9.8949.78 ± 9.28
Month 24 (n =1362, 442)49.22 ± 9.8249.66 ± 9.54
Month 36 (n =857, 286)49.21 ± 9.9550.17 ± 8.20
Month 48 (n =124, 56)50.14 ± 8.9649.60 ± 8.24
SecondaryNumber of Participants With Patient Global Assessment (PtGA) Response of "Clear" or "Almost Clear"

The PtGA evaluated the overall skin disease of participants at that point in time on a single-item. Participants provided their response on a 5-point scale ranges from: 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe. Higher score indicated greater severity of disease. Participants who provided their response as "clear (score of 0)" or "almost clear (score of 1)" in PtGA at each specified visit were reported in this outcome measure.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Number · participants
Number of Participants With Patient Global Assessment (PtGA) Response of "Clear" or "Almost Clear"
participantsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline: Clear (n =2244, 583)13
Baseline: Almost Clear (n =2244, 583)2516
Month 1: Clear (n =2192, 561)211127
Month 1: Almost Clear (n =2192, 561)703246
Month 3: Clear (n =2177, 568)248174
Month 3: Almost Clear (n =2177, 568)762254
Month 6: Clear (n =2030, 562)247176
Month 6: Almost Clear (n =2030, 562)748265
Month 12: Clear (n =1758, 530)209151
Month 12: Almost Clear (n =1758, 530)662236
Month 24: Clear (n =1380, 449)171111
Month 24: Almost Clear (n =1380, 449)502202
Month 36: Clear (n =1112, 377)16275
Month 36: Almost Clear (n =1112, 377)418183
Month 48: Clear (n =410, 125)4025
Month 48: Almost Clear (n =410, 125)15160
SecondaryEuro Quality of Life- 5-Dimensions (EQ-5D)-Utility Scores

EQ-5D: participant rated 5-dimension (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression) questionnaire to assess health-related quality of life in terms of a single utility score. Each dimension was assessed on a 3-point scale (1=no problems, 2=some problems, 3=extreme problems, where higher scores=worse health condition). The responses from the 5 dimensions were used to calculate a single utility index value. Scoring formula developed by EuroQol Group assigned a utility value for each dimension in the profile. Score was transformed and results in a total score range -0.594 to 1.000; higher score indicated a better health state.

Time frame:
Baseline, Month 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
Euro Quality of Life- 5-Dimensions (EQ-5D)-Utility Scores
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline (n =2242, 581)0.77 ± 0.190.80 ± 0.17
Month 6 (n =2021, 559)0.87 ± 0.150.91 ± 0.13
Month 12 (n =1750, 523)0.88 ± 0.150.91 ± 0.13
Month 24 (n =1364, 443)0.88 ± 0.140.90 ± 0.14
Month 36 (n =857, 284)0.88 ± 0.140.91 ± 0.12
Month 48 (n =124, 56)0.90 ± 0.130.89 ± 0.12
SecondaryEuro Quality of Life-5-Dimensions (EQ-5D)-Visual Analogue Scale Scores (VAS)

EQ-5D VAS was a participant rated questionnaire to assess health-related quality of life in terms of a single index value. It was a visual analogue scale that ranged from 0 (minimum) to 100 (maximum), with higher scores indicating a better health condition.

Time frame:
Baseline, Month 6, 12, 24, 36, 48
Reported as:
Mean · units on a scale
Euro Quality of Life-5-Dimensions (EQ-5D)-Visual Analogue Scale Scores (VAS)
units on a scaleTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline (n =2224, 570)66.39 ± 23.2068.21 ± 22.91
Month 6 (n =2026, 559)78.28 ± 17.1183.95 ± 16.18
Month 12 (n =1749, 525)78.91 ± 16.9583.80 ± 14.85
Month 24 (n =1365, 443)79.80 ± 16.9883.47 ± 15.55
Month 36 (n =856, 286)79.43 ± 17.0184.62 ± 14.28
Month 48 (n =124, 56)82.14 ± 14.0784.50 ± 16.87
SecondaryNumber of Participants Who Answered Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU)

Ps-HCRU was a short questionnaire designed to assess healthcare resource use and the impact of psoriasis on work. In the first section, it assessed direct costs associated with healthcare resource use which included participant's interactions with healthcare providers such as general practitioners, dermatologists, cardiologists, gastroenterologists, psychiatrists, surgeons and nurses. When taking the evening dose of tofacitinib, participants were asked to answer the Ps-HCRU questionnaire only if they had an interaction with a healthcare provider or their work was impacted by psoriasis on that specified day. In this outcome measure, number of participants who answered Ps-HCRU at any specified visits were reported.

Time frame:
Baseline, Month 1, 3, 6, 12, 24, 36, 48
Reported as:
Number · participants
Number of Participants Who Answered Psoriasis Healthcare Resource Utilization Questionnaire (Ps-HCRU)
participantsTofacitinib 10 mgTofacitinib 5 mg or 10 mg
Baseline15644
Month 115330
Month 320455
Month 628871
Month 1223471
Month 2417150
Month 3611430
Month 482211

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 10 mg—304/2,281 (13.3%)1,415/2,281 (62%)
Tofacitinib 5 mg or 10 mg—88/586 (15%)394/586 (67.2%)
Most frequent serious events
Showing 10 of 301
Most frequent serious events
EventTofacitinib 10 mgTofacitinib 5 mg or 10 mg
PneumoniaInfections and infestations16/22815/586
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/22814/586
Ankle fractureInjury, poisoning and procedural complications1/22813/586
FallInjury, poisoning and procedural complications0/22813/586
Breast painReproductive system and breast disorders0/6401/203
MetrorrhagiaReproductive system and breast disorders0/6401/203
Pelvic haematomaReproductive system and breast disorders0/6401/203
Angina pectorisCardiac disorders2/22812/586
Myocardial infarctionCardiac disorders6/22812/586
VertigoEar and labyrinth disorders1/22812/586
Most frequent other events
Showing 10 of 16
Most frequent other events
EventTofacitinib 10 mgTofacitinib 5 mg or 10 mg
NasopharyngitisInfections and infestations476/2281122/586
Blood creatine phosphokinase increasedInvestigations294/228192/586
Upper respiratory tract infectionInfections and infestations264/228151/586
DyslipidaemiaMetabolism and nutrition disorders73/228152/586
BronchitisInfections and infestations134/228148/586
HypertensionVascular disorders169/228144/586
ArthralgiaMusculoskeletal and connective tissue disorders164/228140/586
Urinary tract infectionInfections and infestations145/228142/586
PsoriasisSkin and subcutaneous tissue disorders148/228139/586
Gamma-glutamyltransferase increasedInvestigations81/228138/586

Baseline characteristics

Safety analysis set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Tofacitinib 10 mgTofacitinib 5 mg or 10 mgTotal
Mean45.3 ± 12.547.0 ± 13.045.6 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib 10 mgTofacitinib 5 mg or 10 mgTotal
Female640203843
Male16413832024
08

Study locations

323 sites
  • Radiant Research, Inc.
    Birmingham, Alabama 35209, United States
  • UAB Dermatology
    Birmingham, Alabama 35233, United States
  • Horizon Research Group, Inc.
    Mobile, Alabama 36608, United States
  • Radiant Research, Inc.
    Tucson, Arizona 85712, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • Bakersfield Dermatology and Skin Cancer Medical Group
    Bakersfield, California 93309, United States
  • Associates In Research, Inc.
    Fresno, California 93720, United States
  • University of California Irvine
    Irvine, California 92697, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Dermatology Specialists, Inc.
    Oceanside, California 92056, United States
  • MedDerm Associates
    San Diego, California 92103, United States
  • UCSD Dermatology
    San Diego, California 92122, United States
  • University of California San Diego
    San Diego, California 92122, United States
  • University of California San Francisco
    San Francisco, California 94118, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Healthcare Partners Medical Group
    Torrance, California 90503, United States
  • Cherry Creek Research, Inc.
    Denver, Colorado 80209, United States
  • The Savin Center, P.C.
    New Haven, Connecticut 06511, United States
  • New England Research Associates, LLC
    Trumbull, Connecticut 06611, United States
  • Florida Academic Dermatology Center
    Coral Gables, Florida 33134, United States
  • North Florida Dermatology Associates, PA
    Jacksonville, Florida 32204, United States
  • International Dermatology Research, Inc.
    Miami, Florida 33144, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Park Avenue Dermatology, PA
    Orange Park, Florida 32073, United States
  • Leavitt Medical Associates of Florida dba Ameriderm Research
    Ormond Beach, Florida 32174, United States
  • Miami Research Associates, Inc.
    South Miami, Florida 33143, United States
  • Olympian Clinical Research
    Tampa, Florida 33609, United States
  • Atlanta Dermatology, Vein & Research Center, P.C.
    Alpharetta, Georgia 30022, United States
  • Advanced Medical Research, Inc.
    Atlanta, Georgia 30342, United States
  • MedaPhase Inc.
    Newnan, Georgia 30263, United States
  • Altman Dermatology Associates
    Arlington Heights, Illinois 60005, United States
  • Schaumburg Dermatology
    Schaumburg, Illinois 60173, United States
  • NorthShore University Health System - Division of Dermatology
    Skokie, Illinois 60077, United States
  • Springfield Clinic
    Springfield, Illinois 62703, United States
  • Dundee Dermatology
    West Dundee, Illinois 60118, United States
  • Deaconess Clinic Downtown Research Institute
    Evansville, Indiana 47713, United States
  • Hudson Dermatology
    Evansville, Indiana 47714, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46256, United States
  • DermResearch, PLLC
    Louisville, Kentucky 40217, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111-1552, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital - Clinical Unit for Research Trials and Outcomes in Skin
    Boston, Massachusetts 02114, United States
  • Michigan Center for Research Corporation dba Michigan Center for Skin Care Research
    Clinton, Michigan 48038, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • Somerset Skin Centre - Dermcenter
    Troy, Michigan 48084, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Saint Louis University - Department of Dermatology
    Saint Louis, Missouri 63104, United States
  • Skin Specialists, P.C
    Omaha, Nebraska 68144, United States
  • Bettencourt Skin Center
    Henderson, Nevada 89074, United States
  • Dartmouth-Hitchcock Medical Center-Norris Cotton Cancer Center
    Lebanon, New Hampshire 03756, United States
  • Centennial Center-Comprehensive Clinical Research
    Berlin, New Jersey 08009, United States
  • New York University (NYU) School of Medicine - Investigational Pharmacy (IP Shipment, Pharmacy)
    New York, New York 10016, United States
  • NYU Langone Medical Center, Ambulatory Care Center, Department of Dermatology, Clinical Studies Unit
    New York, New York 10016, United States
  • The Rockefeller University
    New York, New York 10065 6307, United States
  • University of North Carolina at Chapel Hill- Hospital
    Chapel Hill, North Carolina 27514, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27516, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Dermatology Consulting Services
    High Point, North Carolina 27262, United States
  • Wake Dermatology Associates, LLC
    Raleigh, North Carolina 27607, United States
  • Wake Research Associates
    Raleigh, North Carolina 27612, United States
  • Dermatology Associates
    Wilmington, North Carolina 28401, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Piedmont Imaging
    Winston-Salem, North Carolina 27103, United States
  • PMG Research of Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • Triad Dermatology, PA
    Winston-Salem, North Carolina 27103, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27104, United States
  • Jewish Hospital
    Cincinnati, Ohio 45236, United States
  • Radiant Research, Inc.
    Cincinnati, Ohio 45249, United States
  • IP ONLY: University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • University Hospitals Case Medical Center/Dept. of Dermatology
    Cleveland, Ohio 44106, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Central Sooner Research
    Norman, Oklahoma 73071, United States
  • Baker Allergy Asthma and Dermatology Research Center, LLC
    Lake Oswego, Oregon 97035, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • University of Pittsburgh Medical Center - Department of Dermatology
    Pittsburgh, Pennsylvania 15213, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Clinical Partners, LLC
    Johnston, Rhode Island 02919, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Office of John Michael Humeniuk, MD
    Greer, South Carolina 29650, United States
  • Radiant Research, Inc.
    Greer, South Carolina 29650, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Rivergate Dermatology Clinical Research Center, PLLC
    Goodlettsville, Tennessee 37072, United States
  • Dermatology Associates of Knoxville PC
    Knoxville, Tennessee 37917, United States
  • Dermatology Research Associates
    Nashville, Tennessee 37203, United States
  • Arlington Research Center, Inc.
    Arlington, Texas 76011, United States
  • Dermatology Treatment & Research Center
    Dallas, Texas 75230, United States
  • Modern Research Associates, PLLC
    Dallas, Texas 75231, United States
  • Menter Dermatology Research Institute
    Dallas, Texas 75246, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Suzanne Bruce and Associates, PA
    Houston, Texas 77056, United States
  • Office of Mark Lee, MD
    San Antonio, Texas 78229, United States
  • Progressive Clinical research, P.A.
    San Antonio, Texas 78229, United States
  • Stephen Miller, MD, PA
    San Antonio, Texas 78249, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23502, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23507, United States
  • Rockwood Research Center
    Spokane, Washington 99202, United States
  • Wenatchee Valley Hospital & Clinics
    Wenatchee, Washington 98801, United States
  • Mountain State Clinical Research
    Bridgeport, West Virginia 26330, United States

Showing the first 100 of 323 sites across 36 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Valenzuela F, Korman NJ, Bissonnette R, Bakos N, Tsai TF, Harper MK, Ports WC, Tan H, Tallman A, Valdez H, Gardner AC. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. Br J Dermatol. 2018 Oct;179(4):853-862. doi: 10.1111/bjd.16798. Epub 2018 Aug 13. PubMed 29782642 ↗

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2010
First posted
Jul 15, 2010
Start
Sep 2010
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Results first posted
Jun 26, 2017
Last update
Jun 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01163253
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 15, 2010
Start date
Sep 2010
Primary completion
Jun 2016
Completion
Jun 2016
Results posted
Jun 26, 2017
Last update
Jun 26, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion